retatrutide phase 3 trials Severe Obesity Trial Shows 30% Weight Loss VisualAbstract: Retatrutide reduces body weight

One phase IIb clinical trial administered setmelanotide to obese participants with heterozygous MC4R deficiency and obese controls over 28 days, observing a placebo-adjusted weight loss of 2.6 kg and 4.0 kg respectively [98]

Semaglutide: Well-characterized over 7+ years

Telehealth Convenience: Zealthys program is entirely online, offering the convenience of accessing all services from the comfort of your home

Red Flags: When to Contact Your Doctor Severe or persistent abdominal pain , especially upper abdominal pain radiating to the back this can signal pancreatitis and requires immediate evaluation

Canadian researchers can review third-party tested retatrutide options through Great Northern Peptides, which offers domestic shipping and product-specific retatrutide pages for research use